a phase II trial of amrubicin and carboplatin for patients with extensive stage small cell lung cancer
Phase 2
- Conditions
- small cell lung cancer
- Registration Number
- JPRN-UMIN000001115
- Lead Sponsor
- agasaki Thoracic Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1. severe cardiac effusion 2. severe supra vena cava syndrome 3. severe complication (angina pectoris, myocardial infarction, heart failure, diabetes, hypertension, infection, interstitial pneumonia) 4. active other cancer 5. pregnancy women 6. need radiotherapy for brain metastasis 7. limited stage small cell lung cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method progression free survival, overall survival, toxicity